MDV, as leronlimab appears to be the biggest an
Post# of 148185
as leronlimab appears to be the biggest and most sudden disruptor that modern medicine has likely seen, do you think it plausible that competition amongst big pharmaceuticals would work to prevent a successful buyout by any one firm?
That certainly is my hope. De. Pourhassan and Kelly would be in a stellar position to play one BP agains the other, to our benefit, but also to the medical community. Multiple BPs developing leronlimab for multiple indications, under lucrative licensing terms, is my hope.
I don’t know if this an unreasonable expectation. It is difficult to believe that every BP is not at some level aware of Cytodyn and the change in medicine that leronlimab is going enable (or force).